Diamond Equity Predicts MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities research analysts at Diamond Equity issued their Q1 2027 earnings estimates for shares of MAIA Biotechnology in a research report issued to clients and investors on Monday, May 18th. Diamond Equity analyst H. Diamond anticipates that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.69) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.46) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04.

MAIA Biotechnology Price Performance

MAIA opened at $1.26 on Tuesday. The firm has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.51. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The company has a market capitalization of $76.61 million, a PE ratio of -1.88 and a beta of 0.21.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Marshall Wace LLP purchased a new position in MAIA Biotechnology during the 2nd quarter valued at approximately $29,000. Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology during the 4th quarter valued at approximately $35,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $52,000. Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology in the first quarter valued at $140,000. Finally, Geode Capital Management LLC grew its holdings in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares in the last quarter. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.